Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Clinical Summary
Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.
Key...
Clinical Summary
Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.
Key...
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Hope Rugo, MD, discusses results from a phase 3 trial evaluating adagloxad simolenin in patients with high-risk early-stage triple-negative breast cancer.
Hope Rugo, MD, discusses results from a phase 3 trial evaluating adagloxad simolenin in patients with high-risk early-stage triple-negative breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Sara Tolaney, MD, discusses results from the phase 3 ASCENT-04 trial, assessing sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Sara Tolaney, MD, discusses results from the phase 3 ASCENT-04 trial, assessing sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial, which evaluated gedatolisib in combination with palbociclib and fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer who experienced disease...
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial, which evaluated gedatolisib in combination with palbociclib and fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer who experienced disease...
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Mary-Ellen Taplin, MD, discusses results from the phase 3 PROTEUS trial assessing perioperative apalutamide plus ADT significantly in high-risk localized or locally advanced prostate cancer.
Mary-Ellen Taplin, MD, discusses results from the phase 3 PROTEUS trial assessing perioperative apalutamide plus ADT significantly in high-risk localized or locally advanced prostate cancer.
Jonathan Goldman, MD, discusses results from the LIBRETTO-432 trial assessing adjuvant selpercatinib in RET fusion-positive non-small cell lung cancer.
Jonathan Goldman, MD, discusses results from the LIBRETTO-432 trial assessing adjuvant selpercatinib in RET fusion-positive non-small cell lung cancer.
Mark Dickson, MD, discusses results from the phase 3 SARC041 trial which demonstrated that abemaciclib significantly improved PFS compared with placebo in patients with recurrent or metastatic dedifferentiated liposarcoma.
Mark Dickson, MD, discusses results from the phase 3 SARC041 trial which demonstrated that abemaciclib significantly improved PFS compared with placebo in patients with recurrent or metastatic dedifferentiated liposarcoma.
Hope Rugo, MD, discusses results from a phase 3 trial evaluating adagloxad simolenin in patients with high-risk early-stage triple-negative breast cancer.
Hope Rugo, MD, discusses results from a phase 3 trial evaluating adagloxad simolenin in patients with high-risk early-stage triple-negative breast cancer.
Elizabeth Budde, MD, PhD, discusses long-term results from the phase 3 SUNMO trial evaluating mosunetuzumab plus polatuzumab vedotin in transplant-ineligible patients with relapsed/refractory large B-cell lymphoma.
Elizabeth Budde, MD, PhD, discusses long-term results from the phase 3 SUNMO trial evaluating mosunetuzumab plus polatuzumab vedotin in transplant-ineligible patients with relapsed/refractory large B-cell lymphoma.
Luca Bertamini, MD, discusses the application of the newly established IMS/IMWG genomic risk classification in newly diagnosed patients with multiple myeloma.
Luca Bertamini, MD, discusses the application of the newly established IMS/IMWG genomic risk classification in newly diagnosed patients with multiple myeloma.
Mattia D'Agostino, MD, discusses long-term MRD analyses from the phase 2 FORTE trial evaluating different induction, consolidation, and maintenance strategies in newly diagnosed patients with multiple myeloma.
Mattia D'Agostino, MD, discusses long-term MRD analyses from the phase 2 FORTE trial evaluating different induction, consolidation, and maintenance strategies in newly diagnosed patients with multiple myeloma.
Atish Choudhury, MD, PhD, discusses a case of oligometastatic hormone-sensitive prostate cancer, exploring the role of metastasis-directed therapy combined with intensified androgen deprivation.
Atish Choudhury, MD, PhD, discusses a case of oligometastatic hormone-sensitive prostate cancer, exploring the role of metastasis-directed therapy combined with intensified androgen deprivation.
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.
Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.
